148 results on '"Rovira, Ana"'
Search Results
2. Data from High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer
3. Data from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
4. Data from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
5. Supplementary Figures and Tables from High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer
6. Supplementary Tables from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
7. Supplementary Tables from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
8. Data from High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer
9. Supplementary Figures and Tables from High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer
10. Supplementary Figures from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
11. Supplementary Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
12. Supplementary Figure S5 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
13. Supplementary Figure S4 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
14. Data from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
15. Supplementary Table 1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
16. Supplementary Figure S1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
17. Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
18. Supplementary Table 2 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
19. Supplementary Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
20. Supplementary Table 2 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
21. Supplementary Figures S1-S3 and Tables S1-S4 from c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer
22. Supplementary Figure S6 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
23. Supplementary Figure S3 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
24. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
25. Supplementary Figure S5 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
26. Supplementary Figure S2 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
27. Supplementary Table 1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
28. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
29. Supplementary Figure S3 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
30. Supplementary figure legends from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
31. Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
32. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
33. Data from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
34. Supplementary Figure S6 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
35. Supplementary figure legends from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
36. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
37. Supplementary Figure S2 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
38. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
39. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
40. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
41. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
42. Data from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
43. Supplementary Figure S1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
44. Supplementary Figure S4 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
45. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
46. Supplementary Figures S1-S3 and Tables S1-S4 from c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer
47. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
48. Supplementary Figure S5 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
49. Supplementary Figure S3 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
50. Supplementary Figure 1 from Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.